Arcus Biosciences heads into the final days of September with an unusual split: options traders have turned sharply bullish while short sellers quietly rebuild positions, and a 25% Gilead-held activist stake adds a layer of corporate governance pressure that few clinical-stage biotechs carry.
The most striking signal this week is in the options market. Call buying has overwhelmed put demand to an extreme degree. The put/call ratio dropped to 0.108 on September 29, more than three standard deviations below its 20-day average of 0.336. That reading is close to the 52-week low of 0.033 and represents one of the most call-heavy setups the stock has seen all year. With the stock down 12% over the past month to $25.65, this level of call demand stands out: traders are not simply rolling hedges, they are making directional bets on a recovery.
Short interest tells a more cautious story. Bears have been adding positions steadily. Short interest climbed roughly 6% over the past week to reach 11% of the free float, around 13.6 million shares. Over the past month, shorts have grown by about 8%. The ORTEX short score has crept up from 62.0 to 63.7 over the same period, reflecting rising pressure. That said, the lending market is not signalling a squeeze. Availability is generous at around 962%, meaning roughly nine shares sit available to borrow for every one already shorted. Cost to borrow is just 0.43%, near the low end of the past six months. Short sellers face no friction building or maintaining positions.
The Street is broadly constructive, though the picture is more nuanced beneath the consensus. TD Cowen initiated coverage with a Buy on September 16. Truist raised its target to $40 from $35 on September 8. Wedbush reiterated its Outperform and $43 target this week. The mean analyst price target is $39.91, implying roughly 55% upside from current levels. Bulls anchor the case on casdatifan's HIF-2alpha mechanism: upcoming ARC-20 readouts in second-line clear cell renal carcinoma could validate a differentiated efficacy and tolerability profile, with the company carrying $775 million in cash through at least the second half of 2028. Bears counter that the investment case is almost entirely binary on casdatifan. The broader pipeline, quemliclustat in pancreatic cancer and earlier-stage inflammatory assets, is assigned little near-term weight. Morgan Stanley remains at Equal-Weight with a $22 target, a significant outlier below the pack and close to the current share price. Factor scores reflect the tension: analyst recommendation divergence ranks in the 92nd percentile, while the short score ranks in the 19th, a high-conviction divergence between optimistic analysts and cautious short sellers.
The ownership structure is worth understanding in this context. Gilead Sciences holds 24.7% of Arcus and has filed a Schedule 13D, making it a formal activist-classified holder on the SEC register. Gilead trimmed slightly from 25.6% to 24.7% in its most recent amendment filed August 7, but remains by far the dominant shareholder and the principal commercial partner for the pipeline. BlackRock added around 1.2 million shares in its latest reported period to hold 12.9%, and FMR added nearly 2.9 million shares to reach 3.2%. Insider activity over the past 90 days has been net negative at around $3 million of sales, though all recorded transactions were under pre-arranged 10b5-1 plans, limiting their signal value. President Juan Jaen sold shares in June and July under such plans, as did the Chief Accounting Officer in August.
Alt data adds one piece of genuine colour. Retail attention has spiked sharply, with a Wikipedia-based attention z-score of 3.96 as of September 21. This measures how much attention the company is drawing relative to its own 90-day history. It is not a revenue or efficacy indicator, but the level of interest is unusual and likely tied to clinical chatter around the upcoming ARC-20 readout window.
Earnings are scheduled for November 3. The past two quarterly prints produced muted single-day reactions of roughly plus or minus 1.6%, with five-day moves staying within 4%. The next print is therefore less about the financial results themselves and more about the clinical update calendar: how the ARC-20 data shapes up relative to the pooled mPFS benchmarks the bull case depends on, and whether Gilead's position in the register moves again before then.
See the live data behind this article on ORTEX.
Open RCUS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
